Astellas Pharma Invests $50 Million in Taysha Gene Therapies to Advance Treatment Programs for Rett Syndrome and Giant Axonal Neuropathy

Trending News 🌥️

Taysha Gene Therapies ($NASDAQ:TSHA) is a biotechnology company focused on developing gene therapies for rare neurological disorders. The company’s two lead clinical programs are TSHA-102 for Rett syndrome and TSHA-103 for giant axonal neuropathy. Rett syndrome is a rare genetic neurological and developmental disorder that affects brain development and causes loss of movement functions and cognitive abilities. There is no cure for Rett syndrome and currently available treatments only address symptoms.

There is a great need for an effective treatment for Rett syndrome. Giant axonal neuropathy is a rare, inherited neurological disorder that damages the axons of nerve cells. This investment will allow Taysha to continue to develop its gene therapy programs and bring them closer to market.

Price History

Taysha’s gene therapy approach is based on delivering corrective genes to patients using adeno-associated viral vectors. This technology has shown promise in early clinical trials, and the company is hopeful that it will be able to provide patients with long-term relief from their symptoms. It is a significant vote of confidence in the company and its technology, and will help accelerate its clinical programs.

VI Analysis

Company’s fundamentals reflect its long term potential, below analysis on TAYSHA GENE THERAPIES are made simple by VI app. Based on VI Star Chart TAYSHA GENE THERAPIES is strong in , medium in asset and weak in dividend, growth, profitability. TAYSHA GENE THERAPIES has an intermediate health score of 5/10 considering its cashflows and debt, might be able to pay off debt and fund future operations. TAYSHA GENE THERAPIES is classified as ‘elephant’, a type of company that is rich in assets after deducting off liabilities. what type of investors may interested in such company. Taysha Gene Therapies is a strong company with good long-term potential.

However, it is weak in dividend, growth, and profitability. It has an intermediate health score, which means it may be able to pay off debt and fund future operations. Taysha Gene Therapies is classified as an ‘elephant,’ meaning it is a company with a lot of assets after liabilities are deducted. This type of company may be of interest to investors who are looking for a company with good long-term potential.

VI Peers

The Company focuses on developing and commercializing gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations. Taysha Gene Therapies Inc’s competitors include uniQure NV, Inozyme Pharma Inc, Sorrento Therapeutics Inc.

– uniQure NV ($NASDAQ:QURE)

UniQure NV is a Dutch holding company that operates in the biopharmaceutical industry. The company researches, develops, and commercializes gene therapies. As of 2022, UniQure NV has a market cap of 884.11M and a Return on Equity of -12.84%. The company’s products are used to treat patients with rare and often fatal diseases.

– Inozyme Pharma Inc ($NASDAQ:INZY)

Inozyme Pharma Inc is a biopharmaceutical company that focuses on developing treatments for disorders of calcification. The company’s lead product candidate, ENB-0040, is in clinical development for the treatment of X-linked hypophosphatemia (XLH), a rare genetic disorder that leads to defective bone formation and kidney dysfunction. Inozyme also has two other product candidates in development for the treatment of autosomal dominant hypophosphatemic rickets (ADHR) and tumoral calcinosis (TC).

Inozyme Pharma Inc has a market cap of 88.72M as of 2022. The company’s Return on Equity is -48.16%. Inozyme Pharma Inc focuses on developing treatments for disorders of calcification. The company’s lead product candidate, ENB-0040, is in clinical development for the treatment of X-linked hypophosphatemia (XLH), a rare genetic disorder that leads to defective bone formation and kidney dysfunction. Inozyme also has two other product candidates in development for the treatment of autosomal dominant hypophosphatemic rickets (ADHR) and tumoral calcinosis (TC).

– Sorrento Therapeutics Inc ($NASDAQ:SRNE)

Sorrento Therapeutics Inc. is a biopharmaceutical company that engages in the research, development, and commercialization of therapies for the treatment of cancer and inflammatory diseases. The company’s market cap is 715.42M as of 2022 and has a return on equity of -190.34%. Sorrento Therapeutics is headquartered in San Diego, California.

Summary

Taysha is a U.S.-based clinical-stage biotechnology company focused on developing gene therapies for rare neurological disorders. Rett syndrome is a rare neurodevelopmental disorder that affects primarily girls and causes intellectual disability, seizures, and impaired motor function. There is no cure for Rett syndrome, and currently available treatments only address symptoms. GAN is a rare progressive neurodegenerative disorder that primarily affects boys and causes progressive loss of motor and sensory function. There is currently no cure for GAN and no approved treatments. “This investment is in line with our strategy to focus on innovative science to address unmet medical needs in rare diseases.”

The company is also developing TSHA-102, a gene therapy in development for the treatment of GAN. TSHA-102 is currently in a Phase 1 clinical trial. “We are pleased to partner with Astellas, a global leader in rare diseases, to advance our programs for Rett syndrome and GAN,” said Ronald G. Crystal, M.D., chairman, CEO and co-founder of Taysha. “This investment will enable us to continue to progress our programs and bring these potentially life-changing therapies to patients.”.